Navigation Links
OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
Date:7/29/2008

OREX-003 Being Developed as an Antipsychotic Agent with Less Potential for

Treatment-Associated Weight Gain and Metabolic Risks

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for a patent application that would provide broad coverage for a pharmaceutical composition of zonisamide in combination with a series of marketed atypical antipsychotics. Orexigen is currently evaluating a combination product, OREX-003, for the treatment of schizophrenia that it hopes would minimize the potential for weight gain or other adverse metabolic consequences often observed in patients receiving atypical antipsychotic medications.

OREX-003 combines a proprietary sustained release formulation of zonisamide plus olanzapine (marketed as Zyprexa(R)). Preclinical studies conducted by Orexigen demonstrated that the addition of zonisamide prevented weight gain and elevated blood glucose associated with olanzapine alone. Zonisamide appears to reverse the olanzapine effects on appetite pathways in the brain as well as directly on peripheral fat cells, resulting in mitigation of weight gain and elevated blood sugar associated with olanzapine treatment. OZ-101, the Company's Phase II proof of concept trial for OREX-003, is scheduled to begin in the third quarter this year.

"This patent represents another successful milestone for Orexigen. If OREX-003 retains the proven efficacy profile of olanzapine while mitigating possible safety concerns, then it will address a significant public health challenge," said Orexigen President and CEO Gary Tollefson, M.D., Ph.D. "Research has indicated that th
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
2. Cara Therapeutics Secures $12.3 Million in Series C Extension Financing
3. United Therapeutics to Announce Second Quarter 2008 Financial Results Before Market Open on Thursday, July 31, 2008
4. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
5. Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment
6. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
7. CV Therapeutics to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008
8. Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008
9. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
10. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
11. Organizational Changes at Silence Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Cynvenio, a cancer diagnostics company focused ... analysis of tumor cells in the bloodstream, today announced ... decision support application powered by CollabRx, Inc. , ... test, Therapy Finder will provide breast cancer patients and ...
(Date:1/15/2014)... More than 5 million Americans are ... 3 seniors will die with Alzheimer’s or another dementia, ... have shocked many Americans into looking for ways to ... tragic age-related cognitive disorders. Jonathan Weisman, president of Biohack ...
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... January 14, 2014 Histogen, Inc., a ... of cells grown under simulated embryonic conditions, today announced ... with Suneva Medical, Inc. for physician-dispensed aesthetic products containing ... , This agreement is an amendment to the existing ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group with ... presented the ,JCA-Mauvernay Award, to Doctor Hirofumi Arakawa from ... his basic research on the ,identification and characterization of ... the University of Tokyo, for his applied research on ...
... the Heart Failure Society of America,s 15th Annual Scientific ... announced that B-type natriuretic peptide (BNP) may have utility ... of decompensation in advance of acute presentations.   ... sponsored by Alere Inc., is the first of its ...
... 4, 2011 Kylin Therapeutics, Inc., a leading ... received a notice of allowance from United States ... U.S. patent application. This newly allowed patent broadly ... expanded areas on Kylin,s proprietary nanoparticle technology platform, ...
Cached Biology Technology:The Japanese Cancer Association and Debiopharm Group™ Present Doctors Arakawa and Kurokawa With the 2011 'JCA-Mauvernay Award' for Their Innovative and Outstanding Research in the Field of Cancer 2The Japanese Cancer Association and Debiopharm Group™ Present Doctors Arakawa and Kurokawa With the 2011 'JCA-Mauvernay Award' for Their Innovative and Outstanding Research in the Field of Cancer 3HABIT Study Highlights Home BNP Testing May Allow for Earlier Interventions and Better Management of Heart Failure Patient 2HABIT Study Highlights Home BNP Testing May Allow for Earlier Interventions and Better Management of Heart Failure Patient 3Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology 2
(Date:7/9/2014)... bladders of healthy women differ from bacteria in ... to researchers from Loyola University Chicago Stritch School ... 9, 2014, in the American Society for Microbiology,s ... communities may play a role in female urinary ... common, yet poorly understood, condition with symptoms similar ...
(Date:7/9/2014)... Regulated deer hunts in Indiana state parks have helped ... damage caused by overabundant populations of white-tailed deer, a ... Michael Jenkins, associate professor of forest ecology, found that ... organizing hunts in state parks has successfully spurred the ... scarce by browsing deer. , Jenkins said that ...
(Date:7/9/2014)... Calif. Sexual selection refers to species, selection for ... special type of natural selection enhances opportunities to mate, ... , Biologists at the University of California, Riverside have ... formation of a placenta are linked. Describing the ... in the family Poeciliidae, the researchers found that species ...
Breaking Biology News(10 mins):Hunting gives deer-damaged forests in state parks a shot at recovery 2Biologists link sexual selection and placenta formation 2Biologists link sexual selection and placenta formation 3Biologists link sexual selection and placenta formation 4
... Texas Medical School at Houston could help experts better decide ... their second pregnancies for a common bacterial infection if they ... Streptococcus, or GBS, is a type of bacterial infection that ... deadly to an infant passing through the mother,s birth canal. ...
... have found a way to pull pure oxygen from ... and a room-temperature glass of water. ,Because oxygen ... using solar electricity to split water into those elements--a ... One of the chief obstacles to that green-energy scenario ...
... WASHINGTON, DC U.S. Department of Energy (DOE) Under ... Agriculture Under Secretary for Research, Education and Economics Gale ... more than $10 million to accelerate fundamental research in ... biofuels offer one of the best near- to mid-term ...
Cached Biology News:Recurrence of group B strep high in subsequent pregnancies, say UT Houston obstetricians 2Water refineries? 2Water refineries? 3DOE and USDA announce more than $10 million in bioenergy plant feedstock research 2
... is an easy-to-use siRNA transfection reagent that ... genes in a variety of cell lines. ... an optimized, straightforward protocol. High levels of ... following transfection of 20 to 100 nM ...
... features of Tracker, plus software that rewards the ... defined period of time in a user defined ... instruments all built around a video camera, frame ... track two fields at once and up to ...
... of movement counts, similar to an infrared beam ... 6 subjects at once, in two frames of ... whole experimental group at once, and allow social ... for a variety of other spatial behavior situations, ...
... An accessory to the Spatial Behavior System. ... either entirely or automatically selected parts, and scoring ... replay or slow replay.The Spatial Behavior line is ... video camera, frame grabber, and feature extraction software ...
Biology Products: